Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application

Inclusion Criteria: * Male or Female patients * 2 to 10 years old. * with light to moderate with no signs of acute/ sub-acute eczema or in activity. * Subjects can not present inflammatory lesions, erythema, edema, eschar, excoriation and lichens. * Subjects can present light to moderate dryness. Exclusion Criteria: * Subjects presenting any serious systemic disease * Subjects with medical history regarding serious asthma * Subjects with known or suspected allergy to one of the investigational products * Subjects with acute atopic eczema or in activity, needing systemic antibiotics * Subjects with signs of active infections on skin * Subjects whose parents or legal guardian seem to have difficulty in understand the informed consent form (ICF) * Female subjects who are not in pre-menarche period. * Subjects who need topic corticoids or any other medication that can interfere on Atopic Dermatitis during the study. * Patient with a wash-out period for treatment less than: * injectable corticoids: 60 days * systemic corticoids: 15 days * topic corticoids: 8 days * topic immunomodulator: 8 days * antihistaminic : 48 hours